Project Grant F30CA298573
Award Date
9/10/25
Completion Date
Not listed
Dollars Obligated
$102K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $626,534 in funding to The Medical University of South Carolina to conduct research aimed at understanding how transient endoplasmic reticulum (ER) stress can enhance the anti-tumor function of T cells. The 5-year project, starting on December 1, 2024, will investigate the mechanisms by which ER stress-induced autophagy can improve mitochondrial function, metabolic programming, and...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $563,233 to The Medical University of South Carolina to investigate strategies for overcoming immunosuppression and improving adoptive T cell therapy for cancer treatment. The key focus is on understanding how the sphingosine kinase 2 (SPHK2) and sphingosine-1-phosphate (S1P) axis regulates the suppressive function of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment....
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $147,486 to the University of Pittsburgh to conduct research on understanding the role of altered lipid metabolism in CD8 T cell exhaustion within the tumor microenvironment. The 3-year project aims to (1) evaluate the impact of abolishing citrate transport on carbon utilization and effector function of CD8 T cells in the tumor microenvironment, and (2) determine the role of stored...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $496,391 to the University of North Carolina at Chapel Hill to conduct research on manipulating lipid metabolism to reverse immune dysfunction in solid cancers. The research aims to discover how the tumor microenvironment impairs the metabolic function of tumor-infiltrating CD8+ T cells, and test whether restricting the enzyme acetyl-CoA carboxylase (ACC) can rewire T cell lipid...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $293,369 to Duke University to conduct research on mechanisms of macrophage-mediated immune evasion in residual tumors. The research aims to uncover potential strategies to target and engineer the immune-mediated clearance of residual tumor cells that can lead to cancer relapse, even after initial response to oncogene-targeted therapies. The award period runs from Aug 1, 2024 to Mar 31,...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $103,948 to the Sloan-Kettering Institute for Cancer Research to investigate mechanisms of T-cell dysfunction in the tumor microenvironment. The research aims to elucidate how amino acid availability impacts translation and cytokine production in tumor-infiltrating T-cells, as well as the role of non-coding RNAs in translational suppression during T-cell exhaustion. The...
This federal Project Grant award of $176,712 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research to investigate the role of CD91-mediated signaling in priming T cell responses to nascent, emerging tumors. The primary awardee, the University of Pittsburgh, will develop a new mouse model to test the importance of CD91-mediated signaling in response to tumor-derived heat shock proteins for cancer immunosurveillance. This research aims to advance the...
This Project Grant award of $162,486 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research at the University of Pittsburgh to investigate the functional consequences of high glucose culture on adoptive T cell therapies for cancer. The key objectives are to: (1) identify cellular proteins that are differentially O-GlcNAcylated in high glucose conditions and determine if inhibiting O-GlcNAcylation can restore T cell cytokine production, antitumor immunity,...
This $351,131 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Miami to mechanistically dissect the signaling interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) that contribute to chemotherapy and immunotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). The goal is to uncover novel insights into the tumor-permissive and tolerogenic role of...
This $674,996 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sanford Burnham Prebys Medical Discovery Institute (SBP) to determine if targeting the PSGL-1 checkpoint inhibitor can promote the development and/or maintenance of CD8+ T cells essential for anti-tumor responses to PD-1 immune checkpoint blockade (ICB) therapy. The key objectives are to evaluate if PSGL-1 blockade can generate or sustain tumor-specific...